Maze Therapeutics
MAZE
75 hedge funds and large institutions have $477M invested in Maze Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
10% more funds holding
Funds holding: 68 → 75 (+7)
8% more capital invested
Capital invested by funds: $441M → $477M (+$35.3M)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
2.78% less ownership
Funds ownership: 91.45% → 88.67% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.07M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$4.56M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$1.61M |
| 4 |
State Street
Boston,
Massachusetts
|
+$832K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$638K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.31M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.38M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$3.02M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$2.75M |
MAZE Hedge Fund Activity: Q2 2025 in Review
75 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q2 2025, worth a combined $477M — up 8% from $441M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MAZE positions and 7 closed out — a net gain of 7 holders — while 25 added to existing stakes and 14 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $7.07M. The largest seller was AllianceBernstein, cutting an estimated $10.2M.
- 75 institutional investors held Maze Therapeutics (MAZE) as of Q2 2025, up from 68 in Q1 2025.
- Funds reported $477M of Maze Therapeutics stock for Q2 2025, up 8% quarter-over-quarter.
- 14 funds opened new Maze Therapeutics positions in Q2 2025 and 7 closed out, a net change of +7 holders.
- The largest Maze Therapeutics buyer in Q2 2025 was Deep Track Capital, an estimated $7.07M added.
- The largest Maze Therapeutics seller in Q2 2025 was AllianceBernstein, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2025.